Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 85.1% | 97.6% | 88.6% | 84.2% | 83.4% | 83.7% | 83.0% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Gross margin is 85.4%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Gross margin for Alnylam Pharmaceuticals, Inc. have been 83.7% over the past three years, and 88.8% over the past five years.
As of today, Alnylam Pharmaceuticals, Inc.'s Gross margin is 85.4%, which is higher than industry median of 65.9%. It indicates that Alnylam Pharmaceuticals, Inc.'s Gross margin is Good.